reatment of bipolar spectrum disorders today is a hot topic, with many new agents now available and many new combinations being touted. However, clinical practice may not always be "in synch" with clinical research, since the treatment of bipolar spectrum disorders with monotherapies as well as with combinations of drugs may now be the least evidence-based area of psychopharmacology practice.
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Evidence-Based Prescribing
The best evidence for efficacy of agents for bipolar spectrum disorders is for monotherapies, especially for acute mania (e.g., lithium, atypical antipsychotics, divalproex) and for maintenance (lithium, olanzapine, and lamotrigine). 3 Recently, numerous combinations have been studied, especially lithium or divalproex combined with an atypical antipsychotic for acute mania or fluoxetine combined with olanzapine for bipolar depression (Table 1) . 3 However, recent analysis of prescribing trends shows that the monotherapies and combinations actually utilized in clinical practice are not those that are the most evidence based.
1,2 For example, there is more gabapentin prescribed for bipolar disorder than lamotrigine, even though there is little compelling evidence for gabapentin's efficacy in bipolar disorder and the FDA has approved lamotrigine for the treatment of bipolar disorder.
1,2 Thus, up to half of bipolar patients receiving combination therapy are given anticonvulsants (such as gabapentin or topiramate) that are not well documented to work for bipolar disorder. [1] [2] [3] Why?
Prescribing-Based Evidence
To facilitate learning, I have attached whimsical names to all the prudent options available to the prescriber to treat bipolar spectrum disorders while the experts clarify the data and remove the controversy (Table 1) .
Anticonvulsants: Perhaps one of the reasons so many anticonvulsants that are not well documented to have efficacy in bipolar disorder are nevertheless prescribed so often in bipolar disorder is due to the mistaken assumption that if a drug is an anticonvulsant, it must work like any other anticonvulsant. 5 However, it appears that only some anticonvulsants, 5 particularly those with actions on voltage sensitive sodium channels, may be effective for bipolar disorder. Those agents without convincing efficacy should get no respect. (I call these "Rodney Dangerfield combos.") Antidepressants: One area in which there is evidence but also controversy is in the use of antidepressants for bipolar disorder. Some experts, for example in the Boston area, 6 believe that antidepressants should be added sparingly (the formula "Boston bipolar brew"), or not at all, to prevent the triggering of mania, hypomania, rapid cycling, or mixed states; whereas other experts, including several from California, 7 believe that antidepressants can be cautiously added for bipolar patients in the depressed state if they are already taking other mood stabilizers and not responding to them (a "California careful cocktail") ( Table 1) . Experts, including some from Tennessee, 8 have shown that augmentation of an antidepressant with an atypical antipsychotic can result in stimultaneous stabilization of activation yet elevation of mood in patients with treatmentresistant 8 or bipolar depression 9 (the "Tennessee mellow afterburner"). Lamotrigine: Despite the recent approval of lamotrigine for the treatment of bipolar disorder, there are very few studies of its combination with other approved agents, such as lithium, divalproex, and atypical antipsychotics. Many clinicians combine these agents already, because it seems rational to combine an agent that works best from "above" to reduce and prevent mania, such as divalproex or lithium, with an agent that works best from "below" to reduce and prevent depression (or "La-Li," "La-Do," and "La-Li-Do").
Drug Combinations for Bipolar
Atypical antipsychotics: The atypicals that have been marketed the longest, especially olanzapine and risperidone, are especially well established as efficacious in clinical practice, particularly for bipolar mania and particularly in combination with lithium and divalproex. 3 Now the newer atypical antipsychotics are emerging, and not just for acute mania, but also for depression associated with bipolar I, bipolar II, and treatment-resistant depression. 3 Thus, the new FDA approvals for bipolar mania for quetiapine and ziprasidone and pending for aripiprazole mean the possibility of adding new options to the treatment formula for bipolar spectrum disorders, including some with less risk of weight gain and perhaps diabetes. 10 Any of these atypicals can be added to lithium, lamotrigine, or divalproex, including for complicated cases that do not respond to 1 or 2 agents (e.g., "Quel kit" for combinations with Seroquel/quetiapine; "Able stabilizer" for combinations with Abilify/aripiprazole; and "Jiminy Crickets" for combinations with ziprasidone [zipa-li and zipa-li-do-la]).
Summary
Current treatment of bipolar disorder is an area of unmet need that multiple new agents, alone and in combination, are beginning to meet. 
Combination
Popular Name
Evidence-Based Prescribing Lithium with any atypical antipsychotic "Atypical-lithium combo" (especially olanzapine, risperidone, and quetiapine) Divalproex with any atypical antipsychotic "Atypical-Depakote combo" (especially olanzapine, risperidone, and quetiapine) Lithium augmentation of antidepressants "Classical combo" Atypical antipsychotic augmentation of antidepressants "Tennessee mellow afterburner" (especially olanzapine augmentation of fluoxetine) Olanzapine-fluoxetine combination "Symbyax" Prescribing-Based Evidence Lamotrigine-lithium "La-Li" Lithium-Depakote (divalproex) "Li-Do" Lamotrigine-Depakote (divalproex) "La-Do" Lamotrigine-lithium-Depakote (divalproex) "La-Li-Do" Any combination of mood stabilizers not including "Boston bipolar brew" an antidepressant Any combination of mood stabilizers that does include "California careful cocktail" an antidepressant Any combination containing ziprasidone (Geodon; "Jiminy Cricket" e.g., zipa-li-do-la; i.e., ziprasidone, lithium, divalproex, and lamotrigine) Any combination containing Seroquel (quetiapine) "Quel kit" Any combination containing Abilify (aripiprazole) "Able stabilizer" Any combination containing an anticonvulsant with "Rodney Dangerfield combo" little or no evidence of efficacy in bipolar disorder ("Can't get no respect"; e.g., gabapentin, topiramate ) a Adapted with permission from Stahl.
3,4
Take-Home Points ◆ Treatment of bipolar spectrum disorders currently includes reducing and preventing mania, hypomania, depression, and dysthymia, as well as mixed, rapid cycling, and treatment-resistant states. ◆ Mood stabilizers for these conditions now include lithium, atypical antipsychotics, some but not all anticonvulsants, and, controversially, antidepressants.
◆ Although most patients with a bipolar spectrum disorder receive 2 or more psychotropic drugs, only a few of these combinations have been extensively studied.
◆ As more evidence is being generated, especially with combinations of 3 or more agents, prescribers must weigh the risks and benefits of commonly utilized combinations, noting how to dose and how to augment with a rational mixture of empirically useful and potentially synergistic mechanisms of action.
